Business Context and Reporting Period
This Form 8-K is a current report filed by Aziyo Biologics, Inc. (trading symbol: AZYO) on June 7, 2021. The filing details the results of the Company's annual meeting of stockholders held on the same date. The Company is incorporated in Delaware and is classified as an emerging growth company.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting results rather than financial performance.
Material Changes and Voting Results
A total of 5,998,231 shares of Class A common stock were present at the meeting, representing approximately 84.56% of the outstanding shares as of the April 13, 2021 record date. The following proposals were approved:
- Election of Directors (Item 1): Maybelle Jordan and W. Matthew Zuga were elected as Class I directors to serve until the 2024 annual meeting.
- Ratification of Auditors (Item 2): The appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm for the year ending December 31, 2021, was ratified.
Voting Breakdown
| Proposal / Director | Votes For | Votes Against / Withheld | Abstained / Broker Non-Votes |
|---|---|---|---|
| Maybelle Jordan (Director) | 5,414,119 | 37,042 (Withheld) | 547,070 (Broker Non-Votes) |
| W. Matthew Zuga (Director) | 5,111,073 | 340,088 (Withheld) | 547,070 (Broker Non-Votes) |
| Ratification of PwC (Auditor) | 5,995,955 | 2,231 | 45 (Abstained) |
Guidance, Outlook, and Risks
The filing text does not provide a clear value for future guidance, management commentary on financial outlook, specific risks, contingencies, or unusual items. The document is limited to reporting the outcome of the shareholder vote.
Key Facts for Investor Verification
- Verify the tenure of the newly elected directors (Maybelle Jordan and W. Matthew Zuga) through the 2024 annual meeting.
- Confirm the engagement of PricewaterhouseCoopers LLP for the fiscal year ending December 31, 2021.
- Note the high level of shareholder participation (84.56%) at the annual meeting.
- Review the Definitive Proxy Statement filed on April 23, 2021, for detailed background on the proposals.